-
H Yokobayashi,
M Sugaya, T Miyagaki,
H Kai,
H Suga,
D Yamada,
Y Minatani,
K Watanabe,
Y Kikuchi,
T Tamaki,
S Sato
[show abstract]
[hide abstract]
ABSTRACT: Background Patients with human immunodeficiency virus (HIV) infection exhibit various skin diseases. HIV-associated eosinophilic folliculitis (EF) and pruritic papular eruption (PPE) are frequently seen. Objective To understand the mechanisms underlying HIV-associated EF and PPE. Methods In order to know frequencies of EF and PPE among patients with HIV infection, we first collected HIV(+) patients who visited dermatology clinic in National Center for Global Health and Medicine during February 2007. We next collected 25 serum samples from HIV(+) patients with skin diseases from May 2008 to May 2010. Eight of 25 patients had EF (EF group), four had PPE (PPE group) and others had non-itchy skin problems such as condyloma acuminatum (no itch group). Results We first confirmed high frequencies of EF (10.7%) and PPE (5.3%) among 75 HIV(+) patients who visited our clinic during one month. We then measured serum levels of CCL11, CCL17, CCL26 and CCL27. Serum CCL17 levels in EF were significantly higher than those of PPE and no itch group. Serum CCL26 and CCL27 levels in EF were higher than those of no itch group. The number of CD4(+) cells in EF was significantly lower than that in no itch group. Conclusion High serum levels of CCL17, CCL26 and CCL27, and low CD4(+) cell counts may account for the development of HIV-associated EF.
Journal of the European Academy of Dermatology and Venereology 06/2012; · 2.98 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: B-cell-activating factor belonging to the tumour necrosis factor family (BAFF) is known for its role in the survival and maturation of B cells. It has been recently suggested that BAFF also plays important roles in T-cell activation in T-cell mediated diseases such as psoriasis.
To investigate the role of BAFF in cutaneous T-cell lymphoma (CTCL).
BAFF messenger RNA (mRNA) expression in skin samples (24 CTCL cases and seven healthy controls) and in skin-derived fibroblasts (five CTCL cases and five healthy controls) was examined by quantitative reverse transcription-polymerase chain reaction. We also performed immunohistochemical staining for BAFF and its receptors. Serum BAFF levels were measured in patients with CTCL (n=46), atopic dermatitis (n=36) or psoriasis (n=27) and 27 healthy controls by enzyme-linked immunosorbent assay.
Lesional skin of CTCL contained higher levels of BAFF mRNA than normal skin and the expression levels correlated with disease activity. BAFF mRNA expression levels were elevated in fibroblasts from CTCL skin. Tumour cells in the lesional skin of CTCL expressed BAFF and its receptors, while fibroblasts expressed only BAFF. Serum BAFF levels of CTCL patients were significantly higher than those of healthy controls and correlated with types of skin lesions and clinical stages. They also significantly correlated with serum soluble interleukin-2 receptor and lactate dehydrogenase levels.
BAFF expression in CTCL skin and serum BAFF levels are significantly increased and correlate with the severity of CTCL. These results suggest that BAFF may have important roles in the development of CTCL.
British Journal of Dermatology 04/2012; 167(2):359-67. · 3.67 Impact Factor
-
T Miyagaki,
M Sugaya,
M Kamata,
H Suga,
S Morimura,
A Tatsuta,
Y Uwajima,
M Yamamoto,
S Shibata,
H Fujita,
Y Asano,
T Kadono,
S Sato,
Y Tada
Clinical and Experimental Dermatology 03/2012; 37(7):792-3. · 1.20 Impact Factor
-
Clinical and Experimental Dermatology 03/2012; 37(4):443-5. · 1.20 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Background CC chemokine ligand (CCL) 18 is expressed by monocytes and dendritic cells (DCs), and has potent chemotactic activity for T cells, B cells and DCs. CCL18 expression is up-regulated in lesional skin of atopic dermatitis and bullous pemphigoid, suggesting its important roles in the development of these skin diseases. Objective To investigate roles of CCL18 in cutaneous T-cell lymphoma (CTCL). Methods The CCL18 messenger RNA (mRNA) expression in CTCL skin (n = 21) and in normal skin (n = 7) was examined by quantitative RT-PCR. CCL18 expression was also examined by immunohistochemistry. Serum CCL18 levels were measured in 38 patients with CTCL and 20 healthy controls by enzyme-linked immunosorbent assay. We also analysed correlation between serum CCL18 levels and other clinical and laboratory data. Results The CTCL lesional skin contained higher levels of CCL18 mRNA than normal skin. CCL18 was expressed by dermal macrophages and DCs in CTCL skin. Serum CCL18 levels in patients with CTCL were significantly higher than those of healthy controls and correlated with types of skin lesions. They also significantly correlated with modified severity-weighted assessment scores, serum sIL-2R, LDH, IL-4, IL-10, IL-31, CCL17 and CCL26 levels. Patients with high serum levels of CCL18 showed significantly poor prognosis compared with those with low CCL18 levels. Conclusion CCL18 mRNA is up-regulated in CTCL lesional skin, and serum CCL18 levels are significantly increased and correlated with the severity of CTCL. These results suggest that CCL18 may be associated with the development of CTCL.
Journal of the European Academy of Dermatology and Venereology 03/2012; · 2.98 Impact Factor
-
T Miyagaki,
M Sugaya,
H Suga,
S Morimura,
M Kamata,
H Ohmatsu,
H Fujita,
Y Asano,
Y Tada,
T Kadono,
S Sato
[show abstract]
[hide abstract]
ABSTRACT: Background CD26 is a multifunctional type II transmembrane glycoprotein, which also exists as a secreted isoform, soluble CD26 (sCD26). The CD26 expression on circulating T cells is decreased in some skin diseases such as cutaneous T-cell lymphoma (CTCL) and psoriasis. It remains to be determined whether sCD26 can be used as a marker of skin diseases or not. Objective To investigate utility of sCD26 as a diagnostic marker of skin diseases in combination with thymus and activation-regulated chemokine (TARC). Methods Serum sCD26 levels were measured using enzyme-linked immunosorbent assay in 130 participants including 32 patients with atopic dermatitis (AD); 45 patients with CTCL; 26 patients with psoriasis; and 27 healthy controls. Results Serum sCD26 levels in patients with CTCL and psoriasis (162.1 ± 80.2 ng/mL and 125.4 ± 82.1 ng/mL respectively) were significantly lower than those of healthy controls (392.6 ± 198.7 ng/mL; P < 0.01 and 0.01 respectively). In patients with CTCL, serum sCD26 levels of patients with advanced stage were 135.0 ± 51.5 ng/mL and they were significantly lower than those with early stage (193.1 ± 96.0 ng/mL; P < 0.05). When we used serum sCD26 and TARC levels for diagnostic criteria, sensitivity, specificity, positive predictive value and negative predictive value for AD, CTCL and psoriasis were 65.2-73.7%, 81.4-97.6%, 65.2-94.4%, and 81.4-88.9% respectively. Conclusion Serum sCD26 levels, combined with serum TARC levels, are helpful in diagnosis of AD, CTCL and psoriasis.
Journal of the European Academy of Dermatology and Venereology 11/2011; · 2.98 Impact Factor
-
S Morimura,
M Sugaya,
H Kai,
T Kato, T Miyagaki,
H Ohmatsu,
S Kagami,
Y Asano,
H Mitsui,
Y Tada,
T Kadono,
S Sato
Clinical and Experimental Dermatology 05/2011; 37(2):181-2. · 1.20 Impact Factor
-
Clinical and Experimental Dermatology 10/2009; 35(4):e143-4. · 1.20 Impact Factor
-
Clinical and Experimental Dermatology 03/2009; 34(4):539-40. · 1.20 Impact Factor
-
T Miyagaki,
M Sugaya,
S Kagami,
H Nakashima,
N Ishiura,
R Watanabe,
H Ohmatsu,
H Fujita,
N Yazawa,
T Kadono,
M Fujimoto,
H Saeki,
K Tamaki
Journal of dermatological science 01/2009; 54(1):45-7. · 3.71 Impact Factor
-
British Journal of Dermatology 07/2008; 159(3):738-40. · 3.67 Impact Factor
